Hy-Vee Voluntarily Recalls Two Short Cuts Vegetable Mix Products Because of Possible Health Risk

If your email program has trouble displaying this email, view as a webpage. Hy-Vee Voluntarily Recalls Two Short Cuts Vegetable Mix Products Because of Possible Health Risk Hy-Vee, Inc., based in West Des Moines, Iowa, is voluntarily recalling two of its Hy-Vee Short Cuts vegetable mix products across its eight-state region (IL, IA, KS, MN, MO, NE, SD, and WI) due to possible contamination with Listeria monocytogenes. The potential for contamination was discovered during routine safety sampling at Hy-Vee's Short Cuts production facility. To date, no illnesses have been reported in connection with these products. Listeria monocytogenes is an organism, which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, Listeria monocytogenes infection can cause miscarriages and stillbirths among pregnant women.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA

MedlinePlus Twitter Update

MedlinePlus.gov medlineplus 25 Nov Four steps to food safety at home: • Clean - wash your fruits/veggies, hands, counters, utensils. • Separate - kee… https://t.co/RG3vvVpNJn Details  |  Retweet       This email was sent to edwardlorilla1986.paxforex@blogger.com.   Follow MedlinePlus on Twitter To change your subscription preferences or stop subscriptions anytime, log in to your User Profile with your email address. For questions or problems with this service, please visit subscriberhelp.govdelivery.com. This is a free service provided by MedlinePlus and the U.S. National Library of Medicine. To contact MedlinePlus, use our form.  U.S. National Library of Medicine · 8600 Rockville Pike · Bethesda, MD 20894 · 888-346-3656

OCD | Native American Heritage Month | Postpartum Depression | Childhood Cancer | Carpal Tunnel Syndrome

OCD signs and symptoms, resources for American Indians and Alaska Natives, a study about postpartum depression, and more.

Wednesday, November 25, 2020   When Unwanted Thoughts Intrude Learn about the signs and symptoms of obsessive-compulsive disorder (OCD). (From NIH News in Health) National Native American Heritage Month Honoring Health: Resources for American Indians and Alaska Natives is an e-newsletter that features a different health topic in each issue. Subscribe today! (From NIH's NIAMS) Postpartum Depression May Last For Years About 5% of women reported persistently high levels of postpartum depression symptoms for three years after giving birth. (From NIH Research Matters) Managing Cancer Information During Your Child's Treatment Parents and pediatric oncology experts discuss how to find credible information and work together as active partners on a child's treatment team. (From NIH's NCI) Carpal Tunnel Syndrome Find out the causes, symptoms, and available treatments for carpal tunnel syndrome. (From NIH's NINDS) This bimonthly newsletter contains resources and tips about healthy living and wellness from across NIH, the nation's medical research agency. To find more trusted health information from NIH, go to https://www.nih.gov/health-information. Update Your E-mail Address | Add Subscriptions | Unsubscribe If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view our Frequently Asked Questions page, our Health Information page, or Search our website. This service is provided to you by the National Institutes of Health. NIH…Turning Discovery Into Health®      This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) · 9000 Rockville Pike · Bethesda MD 20892 · 301-496-4000 / TTY 301-402-9612

NIH Funding Opportunities and Notices

NIBIB is passing along the weekly NIH Guide for Grants and Contracts Table of Contents. Scroll down for information and opportunities that may be of interest. Weekly NIH Funding Opportunities and Notices NIH Guide for Grants and Contracts November 20, 2020   Policy Notices Prohibition on Expending NIH Grant Funds for Covered Telecommunications Equipment or Services (NOT-OD-21-030) National Institutes of Health General Notices Notice of NIH Participation in Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science (NOT-OD-21-011) National Institutes of Health National Center for Complementary and Integrative Health National Cancer Institute National Eye Institute National Human Genome Research Institute National Heart, Lung, and Blood Institute National Institute on Aging National Institute of Allergy and Infectious Diseases National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institute of Biomedical Imaging and Bioengineering Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institute on Drug Abuse National Institute on Deafness and Other Communication Disorders National Institute of Dental and Craniofacial Research National Institute of Diabetes and Digestive and Kidney Diseases National Institute of Environmental Health Sciences National Institute of General Medical Sciences National Institute of Mental Health National Institute on Minority Health and Health Disparities National Institute of Neurological Disorders and Stroke National Institute of Nursing Research National Library of Medicine Office of Behavioral and Social Sciences Research Rollout of Redesigned eRA Commons Home and Landing Screens in January 2021 (NOT-OD-21-028) National Institutes of Health Agency for Healthcare Research and Quality Centers for Disease Control and Prevention Food and Drug Administration Notice of Intent to Reissue Funding Opportunity Announcements "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01)" to Permit Resubmissions (NOT-OD-21-034) NIH Basic Behavioral and Social Science Opportunity Network Eunice Kennedy Shriver National Institute of Child Health and Human Development Request for Information (RFI) Regarding Opportunities for New National Programs at the National Cancer Institutes (NCI) Frederick National Laboratory for Cancer Research (NOT-CA-21-018) National Cancer Institute Notice of Changes to Funding Opportunities Notice of Expiration of PAR-19-370 NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed) (NOT-DE-20-034) National Institute of Dental and Craniofacial Research Notice of Clarification to NIEHS' Participation on PA-21-071, "Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)" (NOT-ES-21-004) National Institute of Environmental Health Sciences Notice of Change: Clarification of Page Limits for RFA-EY-20-001 "NEI Audacious Goals Initiative: Translation-Enabling Models to Evaluate Survival and Integration of Regenerated Neurons in the Visual System (U24 Clinical Trial Not Allowed)" (NOT-EY-21-003) National Eye Institute Notice of Removal of Cost Matching Requirements for RFA-NS-21-010 "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)" (NOT-NS-21-016) National Institute of Neurological Disorders and Stroke Notice of Clarification of SB1 Resubmission/Submission Policy (NOT-OD-21-027) National Institutes of Health Notice Extending Expiration Date and Adding Receipt Date for PAR-18-307: Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional) (NOT-OD-21-031) Office of Disease Prevention National Center for Complementary and Integrative Health National Cancer Institute National Institute on Aging National Institute on Alcohol Abuse and Alcoholism National Institute on Drug Abuse Notice Extending Expiration Date and Adding Receipt Date for PAR-18-324: Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional) (NOT-OD-21-032) Office of Disease Prevention National Center for Complementary and Integrative Health National Cancer Institute National Institute on Aging National Institute on Alcohol Abuse and Alcoholism Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institute on Drug Abuse National Institute on Minority Health and Health Disparities Notices of Intent to Publish Notice of Intent to Publish a Funding Opportunity Announcement for Ocular Surface Innervation from Cell Types to Circuit Functions (U01 Clinical Trial Not Allowed) (NOT-EY-21-005) National Eye Institute Notices of Special Interest Notice of Special Interest (NOSI): Synthetic Biology for Biomedical Applications (NOT-EB-20-017) National Institute of Biomedical Imaging and Bioengineering National Center for Complementary and Integrative Health National Cancer Institute National Institute on Aging National Institute of Allergy and Infectious Diseases Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institute of General Medical Sciences Limited Competition for Emergency Competitive Revisions For Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 from Skin and the Oral Cavity for Rapid Acceleration of Diagnostics Radical (RADx-rad) (NOT-OD-21-035) National Institutes of Health National Heart, Lung, and Blood Institute National Institute of Dental and Craniofacial Research Funding Opportunities Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required) (PAR-20-309) National Institute on Aging Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is February 5, 2021. Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional) (PAR-21-068) National Institute on Aging National Cancer Institute National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institute of Dental and Craniofacial Research National Institute of Diabetes and Digestive and Kidney Diseases National Institute of Mental Health National Institute of Neurological Disorders and Stroke Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below. Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional) (PAR-21-069) National Institute on Aging National Cancer Institute National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institute of Dental and Craniofacial Research National Institute of Diabetes and Digestive and Kidney Diseases National Institute of Neurological Disorders and Stroke Application Receipt Date(s): Not Applicable NIDCR Small Grant Program for New Investigators (R03 Clinical Trial Not Allowed) (PAR-21-084) National Institute of Dental and Craniofacial Research Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is February 16, 2021 Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed) (RFA-CA-21-001) National Cancer Institute National Human Genome Research Institute Application Receipt Date(s): March 10, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) (RFA-CA-21-007) National Cancer Institute Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021 No late applications will be accepted for this Funding Opportunity Announcement. Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) (RFA-CA-21-008) National Cancer Institute Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021 No late applications will be accepted for this Funding Opportunity Announcement. Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trial Optional) (RFA-CA-21-009) National Cancer Institute Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on No late applications will be accepted for this Funding Opportunity Announcement. Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional) (RFA-CA-21-010) National Cancer Institute Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). No late applications will be accepted for this Funding Opportunity Announcement.. Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional) (RFA-CA-21-011) National Cancer Institute Application Receipt Date(s): February 22, 2021; May 27, 2021; Sept 29, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). No late applications will be accepted for this Funding Opportunity Announcement. Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional) (RFA-CA-21-012) National Cancer Institute Application Receipt Date(s): February 22, 2021; May 27, 2021; September 29, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). No late applications will be accepted for this Funding Opportunity Announcement GenitoUrinary Development Molecular Anatomy Project (GUDMAP) - Atlas Projects (U01 Clinical Trial Not Allowed) (RFA-DK-20-013) National Institute of Diabetes and Digestive and Kidney Diseases Application Receipt Date(s): February 18, 2021 Reconfiguration of GenitoUrinary Development Molecular Anatomy Project (GUDMAP) /(Re)Building A Kidney (RBK) Data Hub (U24 Clinical Trial Not Allowed) (RFA-DK-20-014) National Institute of Diabetes and Digestive and Kidney Diseases Application Receipt Date(s): February 18, 2021 Small Vessel VCID Biomarkers Validation Consortium Coordinating Center (U24 Clinical Trial Not Allowed) (RFA-NS-21-004) National Institute of Neurological Disorders and Stroke National Institute on Aging Application Receipt Date(s): March 9, 2021 No late applications will be accepted for this Funding Opportunity Announcement. Small Vessel VCID Biomarker Validation Consortium Sites (U01)(Clinical Trials Not Allowed) (RFA-NS-21-005) National Institute of Neurological Disorders and Stroke National Institute on Aging Application Receipt Date(s): March 9, 2021 No late applications will be accepted for this Funding Opportunity Announcement NIH Funding Opportunities now available in RSS (Really Simple News Syndication) format - click here for details. To UnSubscribe to the NIH Guide Weekly TOC LISTSERV, follow the instructions here. This weekly list can be found here. To join or leave the NIBIB Listserv, please visit this webpage and complete the online form. You can also change your options for the Listserv at this site.

HOME  |  DISCLAIMER  |  POLICIES  |  ACCESSIBILITY  |  FOIA  |  NEWS  |  CONTACT US

SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

---

This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud, on behalf of: National Institute for Biomedical Imaging and Bioengineering · 9000 Rockville Pike, Building 31, Room 1C14, Bethesda, MD 20892